Sherif Eltonsy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sherif Eltonsy has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
Laila Aboulatta
17 shared publicationsAlekhya Lavu
College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
14 shared publicationsLara Haidar
University of Manitoba, Winnipeg, Canada
11 shared publicationsPayam Peymani
11 shared publicationsChristine Leong
University of Manitoba, Winnipeg, Canada
10 shared publicationsChristine Vaccaro
College of Pharmacy University of Manitoba Winnipeg Manitoba Canada
9 shared publications
Latest Publications
- 22 July 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Early Discontinuation of Antidepressants in Mood and Anxiety Disorders
Purpose: Early discontinuation of antidepressants continues to be a major challenge in treating mood and anxiety disorders, despite strong evidence supporting ongoing pharmacotherapy to prevent relapse and enhance long-term outcomes. This narrative review aimed to identify potential patient-level, medication-level, prescriber-level, and system-level factors of early discontinuation and to highlight strategies to improve long-term adherence. Methods: First, guideline recommendations from Canada, the United States, the United Kingdom, Europe, and international bodies were reviewed to contextualize recommended treatment durations. Then, a literature search was performed, including studies published from 2000 to 2025. We used PubMed, Google Scholar, PsycINFO, and Web of Science databases. Findings from observational studies, clinical guidelines, and qualitative research were synthesized to identify key factors contributing to early discontinuation and to outline strategies to improve adherence. Results: Early antidepressant discontinuation was often associated with low socioeconomic status, immigrant background, older age, prior substance use, comorbid psychiatric conditions, and misconceptions about treatment, although findings varied depending on the operational definition and study settings. Medication‑related contributors included adverse effect burden, initiation on tricyclic antidepressants, and cost‑related non-adherence. Prescriber‑level and system‑level contributors included limited follow‑up, high workload, variability in prescribing practices, and communication barriers. Several strategies to improve adherence can be adopted, including patient-centered communication, culturally competent care, selecting well‑tolerated first‑line agents, structured follow‑up, pharmacist‑led support, and digital/telehealth‑based interventions. Conclusions: Early antidepressant discontinuation is common and influenced by intersecting social, clinical, and structural factors, including equity-related determinants. Multifaceted, coordinated approaches, including effective communication, appropriate medication selection, and strengthened follow‑up processes, are needed to improve adherence.
- 22 July 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Early Discontinuation of Antidepressants in Mood and Anxiety Disorders
Purpose: Early discontinuation of antidepressants continues to be a major challenge in treating mood and anxiety disorders, despite strong evidence supporting ongoing pharmacotherapy to prevent relapse and enhance long-term outcomes. This narrative review aimed to identify potential patient-level, medication-level, prescriber-level, and system-level factors of early discontinuation and to highlight strategies to improve long-term adherence. Methods: First, guideline recommendations from Canada, the United States, the United Kingdom, Europe, and international bodies were reviewed to contextualize recommended treatment durations. Then, a literature search was performed, including studies published from 2000 to 2025. We used PubMed, Google Scholar, PsycINFO, and Web of Science databases. Findings from observational studies, clinical guidelines, and qualitative research were synthesized to identify key factors contributing to early discontinuation and to outline strategies to improve adherence. Results: Early antidepressant discontinuation was often associated with low socioeconomic status, immigrant background, older age, prior substance use, comorbid psychiatric conditions, and misconceptions about treatment, although findings varied depending on the operational definition and study settings. Medication‑related contributors included adverse effect burden, initiation on tricyclic antidepressants, and cost‑related non-adherence. Prescriber‑level and system‑level contributors included limited follow‑up, high workload, variability in prescribing practices, and communication barriers. Several strategies to improve adherence can be adopted, including patient-centered communication, culturally competent care, selecting well‑tolerated first‑line agents, structured follow‑up, pharmacist‑led support, and digital/telehealth‑based interventions. Conclusions: Early antidepressant discontinuation is common and influenced by intersecting social, clinical, and structural factors, including equity-related determinants. Multifaceted, coordinated approaches, including effective communication, appropriate medication selection, and strengthened follow‑up processes, are needed to improve adherence.
- Open Access
- 29 June 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004616
Disruptions in perinatal outcomes across Manitoba, Canada: before and over 2 years of the COVID-19 pandemic
Background: The COVID-19 pandemic disrupted healthcare service utilisation, but evidence on its impact on perinatal outcomes is conflicting. We investigated the impact of the pandemic public health measures (eg, lockdowns, reduced healthcare access, altered health-seeking behaviour) on preterm birth (PTB), stillbirth, low birth weight (LBW), small for gestational age, caesarean delivery, breastfeeding initiation (BFI) and neonatal intensive care unit (NICU) admissions. Methods: Using linked administrative health databases, we conducted a population-based study of pregnancies before (January 2008–February 2020) or during (March 2020–March 2022) the pandemic; for the latter period, they were categorised by exposure duration. We conducted interrupted time series analyses using season-adjusted generalised linear models, and analyses were stratified by income. Results: Among 222 636 pregnancies (190 694 prepandemic and 31 942 during pandemic), PTB rates increased from 8% prepandemic to 9.1% during the pandemic, with a 19.0% relative increase overall (p<0.01). In stratified analyses, PTB rose by 27.1% in the lower-income group (8.8% to 10.1%, p=0.01) and by 19.7% in the higher income group (7.3% to 8.2%, p=0.02); however, effect modification by income was statistically non-significant. Pregnancies 100% exposed during the first and second year of the pandemic experienced higher rates of PTB by 15.0% (p=0.01) and 11.6% (p<0.01) compared with the prepandemic period, respectively. The pandemic measures were associated with no changes in stillbirth (0.7‰ vs 0.61%; p=0.37) or NICU admission rates (8.3% vs 8.2%; p=0.69). LBW rates increased from 5.5% to 6.3% (13.9% relative increase, p=0.05). Pregnancies spanning the entire first year of the pandemic experienced higher rates of caesarean deliveries (24.6% relative increase, p<0.01). BFI rates decreased from 82.5% to 81.8% (3.9% relative decrease, p=0.01) compared with prepandemic, followed by a slight increase (p=0.02) during the pandemic period. Conclusions: The COVID-19 pandemic measures were associated with increased PTB and caesarean delivery rates, particularly among pregnancies fully exposed to pandemic measures. Over the 2-year pandemic period, stillbirth, NICU admissions and BFI rates were stable.
- 29 June 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004616
Open AccessDisruptions in perinatal outcomes across Manitoba, Canada: before and over 2 years of the COVID-19 pandemic
Background: The COVID-19 pandemic disrupted healthcare service utilisation, but evidence on its impact on perinatal outcomes is conflicting. We investigated the impact of the pandemic public health measures (eg, lockdowns, reduced healthcare access, altered health-seeking behaviour) on preterm birth (PTB), stillbirth, low birth weight (LBW), small for gestational age, caesarean delivery, breastfeeding initiation (BFI) and neonatal intensive care unit (NICU) admissions. Methods: Using linked administrative health databases, we conducted a population-based study of pregnancies before (January 2008–February 2020) or during (March 2020–March 2022) the pandemic; for the latter period, they were categorised by exposure duration. We conducted interrupted time series analyses using season-adjusted generalised linear models, and analyses were stratified by income. Results: Among 222 636 pregnancies (190 694 prepandemic and 31 942 during pandemic), PTB rates increased from 8% prepandemic to 9.1% during the pandemic, with a 19.0% relative increase overall (p<0.01). In stratified analyses, PTB rose by 27.1% in the lower-income group (8.8% to 10.1%, p=0.01) and by 19.7% in the higher income group (7.3% to 8.2%, p=0.02); however, effect modification by income was statistically non-significant. Pregnancies 100% exposed during the first and second year of the pandemic experienced higher rates of PTB by 15.0% (p=0.01) and 11.6% (p<0.01) compared with the prepandemic period, respectively. The pandemic measures were associated with no changes in stillbirth (0.7‰ vs 0.61%; p=0.37) or NICU admission rates (8.3% vs 8.2%; p=0.69). LBW rates increased from 5.5% to 6.3% (13.9% relative increase, p=0.05). Pregnancies spanning the entire first year of the pandemic experienced higher rates of caesarean deliveries (24.6% relative increase, p<0.01). BFI rates decreased from 82.5% to 81.8% (3.9% relative decrease, p=0.01) compared with prepandemic, followed by a slight increase (p=0.02) during the pandemic period. Conclusions: The COVID-19 pandemic measures were associated with increased PTB and caesarean delivery rates, particularly among pregnancies fully exposed to pandemic measures. Over the 2-year pandemic period, stillbirth, NICU admissions and BFI rates were stable.
- Open Access
- 20 June 2026
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 42 (2) , 481-490
Utilization trends and indications of gabapentin use during pregnancy in Manitoba: A population-based cohort study
- 20 June 2026
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 42 (2) , 481-490
Open AccessUtilization trends and indications of gabapentin use during pregnancy in Manitoba: A population-based cohort study
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (6) , 680-687
Impact of SGLT2 Inhibitors on Kidney Function Among People With HIV: A US Prospective Multisite Study
Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are nephroprotective but are associated with early eGFR decline, also termed “eGFR dip.” Despite elevated risk of kidney disease, this phenomenon is understudied among people with HIV (PWH). Methods: In a 1:1 propensity score–matched cohort study using data from 9 Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites, we compared new SGLT2i users with new users of other antihyperglycemic classes. We estimated adjusted hazard ratios (aHRs) for time to ≥10% and ≥30% eGFR decline using multivariable Cox proportional hazards models and analyzed eGFR change using multivariable linear mixed models. In addition, longer-term eGFR trends over 24 months were visualized using locally weighted scatterplot smoothing (LOWESS) curves. Results: Among 1554 eligible PWH, we obtained 295 matched pairs. Over 6 months, eGFR decline incidence of ≥10% and ≥30% was higher among users of SGLT2i versus other antihyperglycemic classes (58.2% vs. 37.4%; aHR: 1.79; 95% CI: 1.40%–2.28%; and 17.3% vs. 9.8%; aHR: 1.69; 95% CI: 1.05–2.73; respectively). The adjusted mean eGFR change at 6 months was −2.62 mL/min/1.73 m 2 for SGLT2i versus 0.05 mL/min/1.73 m 2 for other classes. Long-term eGFR trends revealed an expected initial decline after SGLT2i initiation, followed by stabilization and a slower subsequent decline compared with other classes. Conclusions: Acute eGFR dips were more common among PWH initiating SGLT2i relative to other antihyperglycemic classes, although overall declines were small, transient, and consistent with the general population. Further research is needed to explore the long-term effects of SGLT2i in PWH.
- 1 June 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (6) , 680-687
Open AccessImpact of SGLT2 Inhibitors on Kidney Function Among People With HIV: A US Prospective Multisite Study
Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are nephroprotective but are associated with early eGFR decline, also termed “eGFR dip.” Despite elevated risk of kidney disease, this phenomenon is understudied among people with HIV (PWH). Methods: In a 1:1 propensity score–matched cohort study using data from 9 Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites, we compared new SGLT2i users with new users of other antihyperglycemic classes. We estimated adjusted hazard ratios (aHRs) for time to ≥10% and ≥30% eGFR decline using multivariable Cox proportional hazards models and analyzed eGFR change using multivariable linear mixed models. In addition, longer-term eGFR trends over 24 months were visualized using locally weighted scatterplot smoothing (LOWESS) curves. Results: Among 1554 eligible PWH, we obtained 295 matched pairs. Over 6 months, eGFR decline incidence of ≥10% and ≥30% was higher among users of SGLT2i versus other antihyperglycemic classes (58.2% vs. 37.4%; aHR: 1.79; 95% CI: 1.40%–2.28%; and 17.3% vs. 9.8%; aHR: 1.69; 95% CI: 1.05–2.73; respectively). The adjusted mean eGFR change at 6 months was −2.62 mL/min/1.73 m 2 for SGLT2i versus 0.05 mL/min/1.73 m 2 for other classes. Long-term eGFR trends revealed an expected initial decline after SGLT2i initiation, followed by stabilization and a slower subsequent decline compared with other classes. Conclusions: Acute eGFR dips were more common among PWH initiating SGLT2i relative to other antihyperglycemic classes, although overall declines were small, transient, and consistent with the general population. Further research is needed to explore the long-term effects of SGLT2i in PWH.
- 22 April 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 37 (6) , 628-636
Cannabis Use and the Risk of Incident Venous Thromboembolism Among People With HIV: A Longitudinal Cohort Study in the United States
People with HIV (PWH) are at an increased risk of venous thromboembolism (VTE), and cannabis use is common in this population. However, evidence of cannabis impact on VTE risk has been conflicting and not well evaluated in PWH. Using data from five Centers for AIDS Research Network of Integrated Clinical Systems sites (2009–2020), we assessed the association between cannabis use and VTE risk. Among 13,646 PWH, 30% reported current cannabis use. In adjusted Cox models, neither former (adjusted hazard ratio [aHR] 0.78, 95% confidence interval (CI) 0.57–1.07) nor current (aHR 0.74, 95% CI 0.51–1.06) cannabis use showed a significant increase in VTE incidence compared with never use. Additionally, no dose-dependent relationship was observed between cannabis use frequency and VTE. Among PWH, cannabis use does not appear to be associated with an elevated risk of VTE. Further research is needed to elucidate the relationship between cannabis and VTE risk in this population.
- 22 April 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 37 (6) , 628-636
Cannabis Use and the Risk of Incident Venous Thromboembolism Among People With HIV: A Longitudinal Cohort Study in the United States
People with HIV (PWH) are at an increased risk of venous thromboembolism (VTE), and cannabis use is common in this population. However, evidence of cannabis impact on VTE risk has been conflicting and not well evaluated in PWH. Using data from five Centers for AIDS Research Network of Integrated Clinical Systems sites (2009–2020), we assessed the association between cannabis use and VTE risk. Among 13,646 PWH, 30% reported current cannabis use. In adjusted Cox models, neither former (adjusted hazard ratio [aHR] 0.78, 95% confidence interval (CI) 0.57–1.07) nor current (aHR 0.74, 95% CI 0.51–1.06) cannabis use showed a significant increase in VTE incidence compared with never use. Additionally, no dose-dependent relationship was observed between cannabis use frequency and VTE. Among PWH, cannabis use does not appear to be associated with an elevated risk of VTE. Further research is needed to elucidate the relationship between cannabis and VTE risk in this population.
- Open Access
- 20 November 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (11) , 1756
COVID-19 Infections Still Occur: How Do Pregnant and Non-Pregnant Individuals Compare? A Study from the Canadian Mother–Child Initiative on Drug Safety in Pregnancy (CAMCCO)
Over 100 million pregnant people worldwide remain at risk of COVID-19. We compared the prevalence of severe COVID-19 in pregnancy and in people of reproductive age, and the risk of adverse pregnancy/neonatal outcomes in those with/without COVID-19 during gestation. In the Canadian Mother–Child Cohort, two sub-cohorts were identified using medical services, prescription medication fillings, hospitalizations, and COVID-19 surveillance testing programs data (28 February 2020–2021). The first included all pregnant people with at least one completed trimester of pregnancy during the study period, stratified on COVID-19 status. The second included all non-pregnant people (aged 15–45) with a positive COVID-19 test during the same period. COVID-19 severity was categorized based on hospital admissions before the end of pregnancy. Associations between COVID-19 during pregnancy and adverse perinatal outcomes were quantified using log-binomial regressions. A total of 150,345 pregnant people (3464 (2.3%) had COVID-19), and 112,073 non-pregnant people with COVID-19 were included. Maternal age at the time of COVID-19 diagnosis/positive test was statistically significantly lower among pregnant individuals compared to those who were not pregnant (96% had less than 40 years vs. 80%, p < 0.001). In pregnancy, COVID-19 was associated with the risk of spontaneous abortions (adjRR 1.76, 95%CI 1.37, 2.25), gestational diabetes (adjRR 1.52, 95%CI 1.18, 1.97), prematurity (adjRR 1.30, 95%CI 1.01, 1.67), and NICU (adjRR 1.32, 95%CI 1.10, 1.59); COVID-19 treatment with medications reduced risks. Severe COVID-19 was more prevalent in pregnancy and was associated with higher risks of adverse maternal/neonatal outcomes. As some countries are pulling back preventive strategies for COVID-19, this study highlights the importance of continued surveillance during pregnancy to prevent adverse pregnancy outcomes.
- 20 November 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (11) , 1756
Open AccessCOVID-19 Infections Still Occur: How Do Pregnant and Non-Pregnant Individuals Compare? A Study from the Canadian Mother–Child Initiative on Drug Safety in Pregnancy (CAMCCO)
Over 100 million pregnant people worldwide remain at risk of COVID-19. We compared the prevalence of severe COVID-19 in pregnancy and in people of reproductive age, and the risk of adverse pregnancy/neonatal outcomes in those with/without COVID-19 during gestation. In the Canadian Mother–Child Cohort, two sub-cohorts were identified using medical services, prescription medication fillings, hospitalizations, and COVID-19 surveillance testing programs data (28 February 2020–2021). The first included all pregnant people with at least one completed trimester of pregnancy during the study period, stratified on COVID-19 status. The second included all non-pregnant people (aged 15–45) with a positive COVID-19 test during the same period. COVID-19 severity was categorized based on hospital admissions before the end of pregnancy. Associations between COVID-19 during pregnancy and adverse perinatal outcomes were quantified using log-binomial regressions. A total of 150,345 pregnant people (3464 (2.3%) had COVID-19), and 112,073 non-pregnant people with COVID-19 were included. Maternal age at the time of COVID-19 diagnosis/positive test was statistically significantly lower among pregnant individuals compared to those who were not pregnant (96% had less than 40 years vs. 80%, p < 0.001). In pregnancy, COVID-19 was associated with the risk of spontaneous abortions (adjRR 1.76, 95%CI 1.37, 2.25), gestational diabetes (adjRR 1.52, 95%CI 1.18, 1.97), prematurity (adjRR 1.30, 95%CI 1.01, 1.67), and NICU (adjRR 1.32, 95%CI 1.10, 1.59); COVID-19 treatment with medications reduced risks. Severe COVID-19 was more prevalent in pregnancy and was associated with higher risks of adverse maternal/neonatal outcomes. As some countries are pulling back preventive strategies for COVID-19, this study highlights the importance of continued surveillance during pregnancy to prevent adverse pregnancy outcomes.
- Open Access
Prevalence and Clinical Significance of Potential Drug–Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study
Background: Drug–drug interactions (DDIs) are frequent and potentially harmful in pediatric cancer patients due to polypharmacy and complex chemotherapy regimens. However, data on DDIs in hospitalized pediatric oncology patients remain limited, particularly in Middle Eastern settings. Methods: In this prospective study, we analyzed prescriptions for hospitalized pediatric oncology patients in Iran to assess the prevalence, severity, and nature of potential DDIs (PDDIs). Chemotherapy and supportive medications were analyzed using two validated databases (Lexi-Interact™ and Drugs.com™) between November 2019 and June 2020. Results: Of 80 patients (median age 8.9 years), 21.2% had at least one documented PDDI. We identified 197 total PDDIs involving 42 unique drug pairs. The most common DDIs included acetaminophen and granisetron (severity rating: moderate). Methotrexate and vincristine were the most frequent antineoplastic DDI pair. Methotrexate alone accounted for 156 interactions. Conclusions: This is the first prospective study from Iran—and the largest in the region—investigating PDDIs in pediatric oncology. The dual-database screening approach improved PDDI detection. Clinical teams should routinely evaluate medication profiles in pediatric cancer patients to minimize avoidable harms from DDIs.
Open AccessPrevalence and Clinical Significance of Potential Drug–Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study
Background: Drug–drug interactions (DDIs) are frequent and potentially harmful in pediatric cancer patients due to polypharmacy and complex chemotherapy regimens. However, data on DDIs in hospitalized pediatric oncology patients remain limited, particularly in Middle Eastern settings. Methods: In this prospective study, we analyzed prescriptions for hospitalized pediatric oncology patients in Iran to assess the prevalence, severity, and nature of potential DDIs (PDDIs). Chemotherapy and supportive medications were analyzed using two validated databases (Lexi-Interact™ and Drugs.com™) between November 2019 and June 2020. Results: Of 80 patients (median age 8.9 years), 21.2% had at least one documented PDDI. We identified 197 total PDDIs involving 42 unique drug pairs. The most common DDIs included acetaminophen and granisetron (severity rating: moderate). Methotrexate and vincristine were the most frequent antineoplastic DDI pair. Methotrexate alone accounted for 156 interactions. Conclusions: This is the first prospective study from Iran—and the largest in the region—investigating PDDIs in pediatric oncology. The dual-database screening approach improved PDDI detection. Clinical teams should routinely evaluate medication profiles in pediatric cancer patients to minimize avoidable harms from DDIs.
- Open Access
- 4 December 2024
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 46
Self-medication among pregnant women in comparison to the general population: a scoping review of the main characteristics
Objective: An in-depth evaluation of the published evidence is needed on self-medication, specifically the evidence focusing on vulnerable groups, such as pregnant women. This scoping review aims to provide an overview of the differences in self-medication prevalence and study characteristics among different groups, while identifying gaps in the literature. Methods: A literature search was […] Abstract Objective: An in-depth evaluation of the published evidence is needed on self-medication, specifically the evidence focusing on vulnerable groups, such as pregnant women. This scoping review aims to provide an overview of the differences in self-medication prevalence and study characteristics among different groups, while identifying gaps in the literature. Methods: A literature search was […]
- 4 December 2024
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 46
Open AccessSelf-medication among pregnant women in comparison to the general population: a scoping review of the main characteristics
Objective: An in-depth evaluation of the published evidence is needed on self-medication, specifically the evidence focusing on vulnerable groups, such as pregnant women. This scoping review aims to provide an overview of the differences in self-medication prevalence and study characteristics among different groups, while identifying gaps in the literature. Methods: A literature search was […] Abstract Objective: An in-depth evaluation of the published evidence is needed on self-medication, specifically the evidence focusing on vulnerable groups, such as pregnant women. This scoping review aims to provide an overview of the differences in self-medication prevalence and study characteristics among different groups, while identifying gaps in the literature. Methods: A literature search was […]